StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
575 Study Matches

A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain

A 16 week double blind treatment period to investigate the safety and effectiveness of 3 doses of the study drug vs placebo for endometriosis related pain.

There will be 8 onsite visits and 2 phone visits, blood will be drawn at the onsite visitsThere is an ediary that must be completed every dayStudy exams include a TVU ultrasound, ECG, vital signs, urine pregnancy tests and blood work

$1477.00

Yes
 

Stephanie Estes
Amyee McMonagle - at amcmonagle@pennstatehealth.psu.edu or 717-531-4484
Medicine: Endocrinology, Diabetes and Metabolism (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05560646
SITE00001406
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
premenopausal women
age 18-49
documented surgical diagnosis of endometriosis
moderate to severe endometriosis pain
regular menstrual cycles

Exclusion Criteria:
hysterectomy or bilateral oophorectomy
chronic pelvic pain not endometriosis related
pregnant or breastfeeding
hereditary abnormal hemoglobin or hemolytic anemia
uncontrolled hypertension
Women's Health
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER (PSCI# 20-133) (GO42784)

The purpose of this study is to compare the effects, good or bad, of giredestrant versus an approved endocrine therapy (a treatment that blocks or removes hormones), on patients with breast cancer. In this study, subjects will get either giredestrant or a drug chosen specifically by the study doctor. Subjects can participate in this study based on breast cancer characteristics, current condition, and how well previous anti-cancer therapies were tolerated.

• You should not join another research study.• For women: If you can become pregnant, you must use a reliable non-hormonal birth control method during the study and for 9 days after your final dose of giredestrant or, if you are in the group receiving approved endocrine therapy prescribed by the study doctor, a period of time that your study doctor will discuss with you. This will be 21 days after if you are prescribed letrozole or anastrozole, 30 days after if you are prescribed exemestane, and 60 days after if you are prescribed tamoxifen. Talk with your study doctor about what birth control method may be best for you. Depending on the study treatment you receive, you might be restricted from donating eggs during this same period. Tell your study doctor right away if you get pregnant during this period. If you get pregnant, the study doctor will want to follow up with you on the outcome of the pregnancy and collect information on the baby.• For men: you must agree to take precautions as outlined below for each treatment arm:–If you are in the group receiving approved endocrine therapy prescribed by the study doctor, you study doctor will discuss with you what precautions you will need to take.–If you are in the group receiving giredestrant, and your partner is pregnant or able to become pregnant, you must use a condom during the study and for 9 days after your final dose of giredestrant. This will be 21 days after if you are prescribed letrozole or anastrozole, 30 days after if you are prescribed exemestane, and 90 days after if you are prescribed tamoxifen. You must not donate sperm during this same period. Tell your study doctor right away if your partner becomes pregnant during these periods. The study doctor or research staff will advise you of the possible risks to your unborn child and will make an effort to contact your partner to get her permission to collect information about the pregnancy and the baby. No matter what your partner decides, you can continue to take part in this study.• You should not use certain medications during this study. Your study doctor will talk to you about these medications.

Yes
 

Monali Vasekar
Kelly Hansard - at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5317
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04961996
STUDY00019397
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants (females, regardless of menopausal status, and males) who are age  18 years at the time of signing the Informed Consent Form
Participants who have documented ER+ tumor by immunohistochemistry, as assessed locally on a primary disease specimen and defined as  1% of tumor cells stained positive according to the ASCO/College of American Pathologists (CAP) guidelines
Participants who have documented HER2- tumor, as assessed locally on a primary disease specimen and defined according to ASCO/CAP guidelines
Participants must have undergone definitive surgery of the primary breast tumor(s)
Participants who received or will be receiving adjuvant chemotherapy must have completed adjuvant chemotherapy prior to randomization

Exclusion Criteria:
Participants who are pregnant or breastfeeding, or intending to become pregnant during the study or within 9 days after the final dose of giredestrant, or within the time period specified per local prescribing guidelines after the final dose of TPC
Participants who have received treatment with investigational therapy within 28 days prior to initiation of study treatment or is currently enrolled in any other type of medical research
Participants receiving or planning to receive a CDK4/6i as adjuvant therapy
Participants who have active cardiac disease or history of cardiac dysfunction
Participants who have been diagnosed with Stage IV breast cancer
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Effects of heating on exercise pressor reflex in peripheral artery disease: Exercise Ability

To determine if the sympathetic and blood pressure (BP) responses to exercise will be attenuated during and after heat exposure in patients with peripheral artery disease (PAD).

There will be up to 6 visits at the Hershey Medical Center.The visits involve walking on a treadmill, sitting in a warm or neutral temperature bath, wearing a heat suit, and having one or both of your legs in a warm bath.

You will receive $25 per hour for your participation in this research study

Yes
 

Jian Cui
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03900832
STUDY00005798
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
healthy females and males
all minorities and ethnicies included
free of acute or chronic medical conditions
over 21 years old

Exclusion Criteria:
Females who are pregnant or lactating
under 21 years old
Decisional impairment
Heart & Vascular
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Randomized Controlled Pilot Study of the Use of Cannabidiol in the Management of Endometriosis Pain

We are looking to conduct a study looking at the effects of cannabidiol (CBD) in patients with endometriosis. We believe that CBD will improve both pain and quality of life. The study will last a total of 12 weeks and involve several onsite visits in addition to daily pain assessments.

There will be five in person visitsblood will be drawn at all of these visits

$175

Yes
 

Kristin Riley
Robinn Moyer - at rmoyer3@pennstatehealth.psu.edu or 717-531-6272
Obstetrics and Gynecology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04527003
STUDY00013752
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Females ages 18-45 years at the time of enrollment
Diagnosed with endometriosis by surgical diagnosis with direct visualization and/or histopathologic confirmation of endometriosis

Exclusion Criteria:
Women that are pregnant, breastfeeding or trying to conceive
Women with chronic daily opioid use ( > 14 days / month)
Women that are currently using Cannabis based products
Non-English speaking or inability to read and understand English
Pain Management, Women's Health
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Eye-hand coordination during upright stance

The study will determine how the brain controls eye and hand movements during quiet upright stance.

There will be one visit to the lab (approximately 2 hours) in which participants will be required to make reaching movements towards virtual targets while standing upright. Participants will be required to wear comfortable shoes.

$20

Yes
 

Tarkeshwar Singh
Tarkeshwar Singh - at tsingh@psu.edu or 814-865-7851
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019952
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1)Participants should be between 18-65 years old
3)Participants will be right-hand dominant individuals
4)They will have normal or corrected-to-normal vision
5)Participants should be able to stand upright for long periods (up to 2 and a half hours) with rest every 5-10 minutes or as requested by the participant
6)Participants should be able to grasp a handle and move objects with both hands

Exclusion Criteria:
Any history of neurological disorders (e.g., Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis)
Any history of musculoskeletal disorders (e.g., carpal tunnel syndrome)
Any history of cardiovascular disease (e.g., Coronary Artery disease, Peripheral Artery disease, Carotid Artery disease, Hypertension, Congenital Heart disease, Congestive Heart failure, Myocardial Infarction, Cardiac Arrythmias, Stroke).
Any history of conditions or diseases that increase risk for syncope (e.g., Anemia, Myocardial Ischemia, Kidney disease).
Any history of conditions or diseases of the vestibular system
Neurology, Vision & Eyes
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Multimodal brain MRI-guided understanding of non-motor outcomes in Parkinson's post DBS

This study will explore the relationship between multimodal brain MRI findings and cognitive/mood outcomes in Parkinson's Disease (PD) patients following Deep Brain Stimulation (DBS). Patients already planning to undergo DBS for PD who choose to take part in this study will have study visits before and after DBS to collect motor, neurobehavioral and physical therapy measurements.

Patients who are already planning to undergo DBS for PD who choose to take part in this study will have study visits before and after DBS surgery to collect motor, neurobehavioral and physical therapy measurements. While many of these components are part of as standard of care, some assessments will need to be collected specifically for research purposes. There are two in-person visits (one before DBS surgery and one approximately 3-6 months after surgery). As part of the study, an MRI to gather data to answer our research questions will be conducted. This is in addition to the clinical MRI that is part of the regular assessment to determine if an individual is suitable for the DBS surgery.

$130 if components of study are completed

Yes
 

Sol De Jesus
Amanda Snyder - at TBRC@pennstatehealth.psu.edu or 717-531-5233
Neurology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00016574
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age at least 18
Diagnosed with Parkinson's Disease
Undergoing DBS as part of standard of care
Able to provide informed consent

Exclusion Criteria:
Age less than 18
General contraindications to surgery
Pregnant or nursing women
Unable to undergo MRI for any reason
Atypical Parkinsonism
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Using Exercise to Relieve Arthralgia (Joint Pain) and Improve AI Adherence in Older Survivors (REJOIN): A Pilot Study

Briefly, the purpose of this study is to use a self-management approach (combining education and exercise) to help older breast cancer survivors manage joint pain, a common side effect of aromatase inhibitors (AIs), a medication used to reduce hormones that might increase risk of recurrence and mortality following primary cancer treatment. We believe that reducing joint pain might help survivors take their medication longer and thus improve survival outcomes, compared to standard care.

Attend 4 in person visits, blood will be drawn at each visit.Complete physical function tests and surveys.Wear accelerometer for 7 days following each visit.Randomly selected participants will attend group exercise sessions twice a week for eight weeks via video call and record exercise activities between visits.

$160

Yes
 

Nancy Olsen
Nancy Olsen - at nolsen@pennstatehealth.psu.edu
Medicine: Rheumatology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03955627
STUDY00010776
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 60 and older
Female
Breast Cancer Survivor
Preparing to Start AI medication
ER+ diagnosis

Exclusion Criteria:
Already taking AI medication (greater than 24 weeks)
Gross Cognitive Impairment
Recent Joint Surgery
Cardiac event/Stroke within last 6 months
Not willing to come to HMC for Exercise Sessions
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Assessment of nocturnal hypoventilation in amyotrophic lateral sclerosis

The overall goals of this study are to identify how measurement of carbon dioxide during sleep can improve recognition of respiratory distress in neuromuscular disease and thus improve timely access to respiratory therapies which prolong survival. Subjects in this study will participate for up to one year, during which their carbon dioxide levels will be measured in clinic and in their homes during sleep.

Subjects in this study will participate for up to one year, during which their carbon dioxide levels will be measured using deviced attached to the skin while in clinic and in their homes during sleep. Subjects will also complete surveys at the time of clinic visits.

50

Yes
 

Andrew Geronimo
Andrew Geronimo - at ageronimo@pennstatehealth.psu.edu
Neurosurgery (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00017603
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of amyotrophic lateral sclerosis
18 years of age or older.
Plan to be followed up in person in the Hershey ALS Clinic for the next 12 months.
Experiencing early respiratory change.
Able to perform or have assistance performing home CO2 measurements.

Exclusion Criteria:
In hospice or in active transition to hospice
Use of any type of non-invasive ventilation, except in the case of CPAP for obstructive sleep apnea, or have a tracheostomy
Use of diaphragm pacer
Pre-existing pulmonary disease requiring supplemental oxygen for any portion of the day or night
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 23-121 Phase III Randomized Trial of Stereotactic ablativeradiotherapy (SAbR) for Oligometastatic Advanced RenalCarcinoma (SOAR)

This study is looking at patients with oligometastasis comparing chemotherapy and SABR with chemotherapy alone

•Blood counts and blood chemistry done at initiation and every three months to make sure you are not having any side effects from the study affecting your blood counts.•CT or MRI scans done at initiation and every three months to monitor the response of the treatment to your cancer•Physical exams done every three months to confirm your general well-being and to detect side effects from the study.Compete physical and well being form as set below:•Baseline•3 months from start of treatment•6 months from start of treatment•9 months from start of treatment•12 months from start of treatment•18 months from start of treatment•24 months from start of treatment

Yes
 

Stuthi Perimbeti
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05863351
STUDY00023912
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
must be 18 or older
patient may not have brain metastases
Patient may have any RCC histology except a histology that has a sarcomatoid component.
Patient must have a pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma (RCC) prior to randomization.
Patient must have primary site addressed by local therapy. If the primary RCC is intact, the patient must undergo local treatment to the primary before randomization.

Exclusion Criteria:
Patient must not have received any prior systemic therapy (except for adjuvant setting, see 3.1.9) for metastatic RCC.
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used
Patients must not expect to conceive until after 6 months after the last dose of protocol medication
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
In order to participate in the QOL portion of the protocol, the patient must speak English or Spanish.
Kidney & Urinary System, Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The association between perceived parenting styles, intolerance of uncertainty, and anxiety among young adults

This study aims to understand the association between young adults' perceived parenting, intolerance of uncertainty, and trait anxiety. Participant will be asked to complete a questionnaire that aims to answer the environment and parenting beliefs around which they were brought up, and if they face stressors and anxieties associated with them. This is a correlational study

No
 

Aishwarya Sastry
Aishwarya Sastry - at ams9680@psu.edu
Behavioral Sciences and Education (HARRISBURG)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00015652
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-34 years old
Geographical location: USA
All genders
All ethnicities

Exclusion Criteria:
Individuals below 18 years
Individuals over 34 years
Individuals residing outside USA
Prevention, Education, Mental & Behavioral Health
I'm interested
Share via email

The Use of Micro-Doppler Radar to Identify Service Members at Risk for Musculoskeletal Injury: A Gold Standard Comparison

The purpose of this research study is to see if we can use micro-doppler signal technology to determine if someone has had an ACL reconstruction in the past. We will do this by comparing a group of people who have had the surgery against a group who has never had this surgery to see if this technology can tell the difference.

If you join this study you would be asked to come to a one-hour appointment at the Lebanon Valley College campus in Annville, PA and perform a variety of activities that are part of daily life, such as walking, jumping, and standing from a seated position. We'll ask you to complete a questionnaire on any musculoskeletal pain you're experiencing and report your demographic information.

50

Yes
 

Cayce Onks
Leonard Kishel - at lkishel@pennstatehealth.psu.edu or 717-531-0003, ext=321657
Family and Community Medicine (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00020118
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 18-40
ACL Group: ACL Reconstruction surgery 9-72 months prior and approved to return to normal activities
Control group: No history of lower extremity surgery
Able to provide consent and read/write in English
No current musculoskeletal injuries

Exclusion Criteria:
Prisoner
Pregnant person
any surgery within 6 months of the study visit
Unable to provide consent or read/write in English
Unable to perform movements consistent with daily activities such as walking, jumping, or moving from sit to stand
Prevention, Sports Medicine, Muscle & Bone
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The effects of local negative pressure on forearm and skin blood flow in humans

This study continues our exploration into the mechanisms underlying the control of blood flow. During the experiments, we noninvasively measure skin blood flow (SkBF) and forearm blood flow (FBF) with a FLPI and venous occlusion plethysmography (VOP), respectively. The FLPI uses a low energy laser to measure SkBF. VOP uses blood pressure cuffs on the upper arm and wrist, and an elastic strain gauge encircling the forearm between the cuffs to measure the change in forearm-circumference over time from which we calculate FBF. For each experiment, we collect SkBF and FBF data for a 20-minute baseline, expose the skin of the forearms to negative pressure and then collect SkBF and FBF data for an additional 30-90 minutes. Each subject participates in 2 experiments that differ only in the protocol for the application of negative pressure (i.e. continuous, pulse).

Yes
 

Lacy Alexander
Gabie Dillon - at gad27@psu.edu
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00012607
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women aged 18-40 years

Exclusion Criteria:
•Diagnosed cardiovascular, metabolic, or dermatological conditions that may impact the outcome measures of interest.
•Individuals that use nicotine-containing products
Illicit or recreational drug-use
•Taking corticosteroids, anticoagulants, NSAIDS, or blood thinners
Pregnancy
Heart & Vascular
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

TMIST_EA1151

This study is being done to answer the following question:Can tomosynthesis mammography, three-dimensional x-ray imaging of the breast, lower your chance of developing life-threatening breast cancer through routine screening compared with digital mammography, two-dimensional x-ray imaging of the breast?We are doing this study because we want to find out which of the two usual approaches to breast cancer screening are better in the early detection of life-threatening breast cancers.

Yes
 

Rebecca Sivarajah
Swati Shah - at sshah@pennstatehealth.psu.edu
Radiology (HERSHEY)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
NCT03233191
SITE00000587
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women age 45 or older and under age 75 at the time of study entry
Patients must be scheduled for, or have intent to schedule, a screening mammogram.
Patients must be able to tolerate digital breast tomosynthesis and fullfield digital mammographic imaging required by protocol.
Patients must be willing and able to provide a written informed consent.

Exclusion Criteria:
Women of childbearing potential must not be known to be pregnant or lactating.
Patients must not have new symptoms or signs of benign or malignant breast disease
Patients must not have had a screening mammogram within the last 11 months prior to date of randomization.
Patients must not have previous personal history of breast cancer including ductal carcinoma in situ
Patients must not currently have breast enhancements (e.g., implants or injections).
Prevention, Cancer, Women's Health
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase II/III Study of Maintenance Nivolumab versus Observation in HPV Positive OPCA (PSCI# 20-016) (EA3161)

The purpose of this study is to compare the usual treatment alone (radiation and chemotherapy) to adding maintenance nivolumab to the usual treatment. The addition of nivolumab to the usual treatment could shrink your cancer or prevent it from returning. But, it could also cause side effects, which are described in the risks section below.This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the nivolumab increases the lifetime of the patient without progression for 10 years.This immunotherapy drug, nivolumab, is already approved by the FDA for use in advanced and incurable head and neck cancer. But, most of the time it is not used until the cancer is very advanced and chemotherapy stops working. In this study we believe the use of nivolumab has a chance of preventing the cancer from coming back for patients with your type of cancer. There will be about 286 people taking part in the first part (phase II) of the study and 458 more people taking part in second part (phase III), if the results of the phase II portion are promising and if there is evidence that nivolumab may prolong your life.

The purpose of this study is to compare the usual treatment alone (radiation and chemotherapy) to adding maintenance nivolumab to the usual treatment.

Yes
 

Mitchell Machtay
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03811015
SITE00000750
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age ≥ 18 years.
ECOG performance status of 0 or 1.
Patients must have oropharynx cancer that is p16-positive by immunohistochemistry
Adequate baseline organ and marrow function
Adequate baseline liver functionality

Exclusion Criteria:
Patients with a history of allergic reactions attributed to platinum based chemotherapy agents
Patients must not have had prior systemic therapy or radiation treatment for p16 positive OPSCC
Patients must not have received previous irradiation for head and neck, tumor, skull base, or brain tumors
Patients must not have known hypersensitivity to nivolumab
Patients with evidence of distant metastases or leptomeningeal disease are excluded
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 21-160: A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

The purpose of the study is to evaluate the potential interaction between ASTX727 and venetoclax, the study drugs, evaluate the safety when the study drugs are taken together, and any potential benefits of taking the study drugs together.

The study is expected to last about 20 months. The amount of time you will be on study treatment or be followed up for health information as part of the study depends on how you respond to and tolerate the study treatment.Study assessments/procedures will occur during screening, a period in which your eligibility to enter the study is determined, while on treatment, at treatment discontinuation, when you decide to or are taken off the study treatment, and during the safety follow-up period. While in the study you must follow the directions given to you by the study staff. If you do not follow the directions given to you, you may not be able to continue taking part in the study. You must come to the study center for all visits, including the follow-up visit after your last dose of study treatment, unless you are told a telephone call is an acceptable option.

Yes
 

Hong Zheng
PSCI-CTO at PSCI-CTO@pennstatehealth.psu.edu
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04657081
STUDY00019518
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participant must be 18 years of age or older.
Newly diagnosed AML by World Health Organization (WHO) 2016 criteria
For Phase 1, ECOG 0-2. For Phase 2, ECOG 0-3.
Projected life expectancy of at least 3 months.

Exclusion Criteria:
Known active central nervous system involvement from AML.
Known active hepatitis B or C infection
Known human immunodeficiency virus (HIV) infection
Severe renal impairment
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Factors Influencing the Decision to Report Sexual Violence on Campus

Research project to understand why students do or do not choose to report sexual assault exposure to police or university officials.

One interview via video conferencing or in person.Optional follow up interview via video conferencing.

$35 for initial interviews; $12 for follow ups

No
 

Kamaria Porter
Kamaria Porter - at porterkb@psu.edu
Education Policy Studies (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021495
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Woman (cis-gender, nonbinary, Trans women)
experienced unwanted sex, assault, or harassment during higher education study
currently in undergraduate or graduate program
recently graduated, transferred, or pausing higher education program
Racial background is Black, Afro-Latina, Afro-Indigenous, Black Multiracial

Exclusion Criteria:
did not experienced unwanted sex, assault, or harassment during higher education study
Education, Women's Health
Not applicable
I'm interested
Share via email

Angiotensin-(1-7) Cardiovascular Effects in Aging

We will investigate the effects of acute intravenous infusion of the hormone, angiotensin-(1-7), on cardiovascular function in healthy older adults in a randomized, double blind, placebo-controlled, crossover study.

Participation in this study will include three separate visits to the Clinical Research Center within the Penn State Milton S. Hershey Medical Center. Participants will first have a screening visit to determine if they are able to participate in this study. If eligible based on the screening visit, they will participate in two study visits separated by at least one week. At each study visit, they will be infused with doses of a placebo or angiotensin-(1-7) for about two hours. Before and at the end of the infusion, we will measure blood pressure and blood flow, nerve activity with an acupuncture-type needle in your leg, and collect blood samples from a small plastic tube (catheter) placed in the arm. Cells will also be collected from inside the vein using the catheter if the participant is willing.The study visits will include intravenous infusion of angiotensin-(1-7) or saline for approximately two hours, starting with increasing doses and holding at a steady-state dose. Endothelial function will be measured and blood samples and endothelial cells (if willing) will be collected at baseline and at the end of infusions. Blood pressure, heart rate, and muscle sympathetic nerve activity via microneurography will be measured throughout the study.

$25 per hour; additional $25 per study visit for cell collection

Yes
 

Amy Arnold
Aimee Cauffman - at acauffman@pennstatehealth.psu.edu or 717-531-1617
Neural and Behavioral Sciences (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT05301192
STUDY00017401
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 65 to 80 years
Body Mass Index between 18.5-30 kg/m2
Blood pressure less than 130/80 without medication
No serious chronic medical problems
Fluent in written and spoken English

Exclusion Criteria:
Current smokers
History of cardiovascular, liver, or kidney disease
Taking certain medications (such as SNRIs, NET inhibitors, anticoagulants, glucocorticoids)
Women who are pregnant, nursing, or taking hormone replacement therapy
Evidence of diabetes
Heart & Vascular
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Heart Rate Variability in Orthostatic Hypertension

The study will examine a condition known as orthostatic hypertension, which is a sudden increase in blood pressure when a person stands up. Orthostatic hypertension is a recognized risk factor for cardiovascular diseases. This project will also examine the differences in blood pressure responses to standing between African Americans and other races, since African Americans are more likely to develop high blood pressure than other races.

If you are eligible, you will be asked to complete the following activities in a single visit:• Lie down for 10 minutes while the team completes anelectrocardiogram (EKG) and blood pressure measurements• Stand up for 10 minutes while the team continues the EKGand blood pressure measurements

$25

Yes
 

Jian Cui
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00017924
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
21 – 80 years of age
Are capable of giving informed consent
Are of any race or ethnicity
Can stand for over 10 minutes

Exclusion Criteria:
Age < 21 years of age or > 80 years of age.
Are pregnant or nursing women
Have a history of low blood pressure with standing or passing out.
Cannot stand for 10 minutes
History of blood clots
Men's Health, Heart & Vascular, Women's Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Investigation of Digital Media Use, Anxiety, and Biobehavioral Emotion Regulation in Adolescents

Over the past few decades, the social world of teens has been transformed by the use of digital technology. This study will examine associations between digital media use and emotions in adolescents' daily lives.Youth and their parent will complete questionnaires and semi-structured clinical interviews regarding the youth’s emotions, social experiences, and possible anxiety symptoms. For 10 consecutive days, youth will complete one computerized task once per day and four mini questionnaires via the Wear-It app on the youth's mobile device.Some youth will also participate in a lab visit that will last approximately two hours. Six months later, all youth will be asked to repeat one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device.One year after enrollment, participants will complete final questionnaires, interviews, one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device. Some youth will also participate in a lab visit that will last approximately two hours.

Over the past few decades, the social world of teens has been transformed by the use of digital technology. This study will examine associations between digital media use and emotions in adolescents' daily lives.Youth and their parent will complete questionnaires and semi-structured clinical interviews regarding the youth’s emotions, social experiences, and possible anxiety symptoms. For 10 consecutive days, youth will complete one computerized task once per day and four mini questionnaires via the Wear-It app on the youth's mobile device.Some youth will also participate in a lab visit that will last approximately two hours. Six months later, all youth will be asked to repeat one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device.One year after enrollment, participants will complete final questionnaires, interviews, one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device. Some youth will also participate in a lab visit that will last approximately two hours.

$495

No
 

Sarah Myruski
Stacey LeVan - at sls217@psu.edu or 814-863-6485
Psychology (UNIVERSITY PARK)
 

All
All
This study is also accepting healthy volunteers
NCT00000000
STUDY00023358
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Youth age 14-16.9 with a parent
Speak, write and read English
Must reside and participate from the US

Exclusion Criteria:
Not able to speak, write or read in English
Neurological disorders (ie, Autism, seizures)
Youth of parent not between 14-16.9 years of age
Those not residing in or participating from the US
Mental & Behavioral Health
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov

Strengths, Outcomes, Adversity, and Resilience in College-Aged Childhood Cancer Survivors: The PSU SOAR Study

The purpose of this study is to analyze the strengths, outcomes, adversity, and resilience, as indicated by self-reported experiences in college students who may or may not be childhood cancer survivors. We are asking college students aged 18-23 years attending 4 year universities in the United States to report on their childhood health experiences and their current mental, physical, and social well being during college using a confidential survey. We plan to recruit students who have or have not had a childhood history of cancer and will also ask questions about their demographic information and health habits.

The participants will be asked to complete a confidential online survey that will take 10-15 minutes to complete.

Participants are eligible to earn a $75 Amazon gift card through a random drawing that they can choose to enter after submitting their survey responses

No
 

Laura Klein
Nikolette Nolte - at nmn5225@psu.edu or 484-268-6550
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019071
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 18-23 years
College student attending 4 year university
English as primary language

Exclusion Criteria:
Younger than 18 years or older than 23 years
Not attending a 4 year university
Does not have English as primary language
Mental & Behavioral Health, Cancer
Not applicable
I'm interested
Share via email

The role of thromboxane A2 and its receptor in vascular regulation in women with endometriosis

Women with endometriosis have more thromboxane being produced in their platelets. Thromboxane affects blood vessels, making them constrict, and sensory nerves, making them more sensitive. This study will determine if women with endometriosis are negatively effected by the excess thromboxane.

There will be three in-person visits: one screening and two experimental visits. Participants will take aspirin before one visit and a placebo before the other then will undergo brief tests of nerve sensitivity and a blood draw.

$150

Yes
 

Lacy Alexander
Sue Slimak - at sks31@psu.edu or 814-863-8556
Kinesiology (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
NCT05962034
STUDY00021851
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-48 years
born with a uterus
with and without endometriosis

Exclusion Criteria:
diagnosed cardiovascular disease
hormone replacement therapy within previous 2 months
nicotine use
pregnant or breastfeeding
aspirin allergy or hypersensitivity
Heart & Vascular, Pain Management, Women's Health
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,
State College, PA ,

Interlimb differences in Motor Control and Learning

This study examines how each brain hemisphere contributes to motor control and coordination. Participants play virtual reality/computer games to look at how their arms move during different activities.

Yes
 

Robert Sainburg
Brooke Fosaaen - at sainburglab@psu.edu or 814-865-7937
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
PRAMS00040722
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
over the age of 18

Exclusion Criteria:
neurological disease
upper-extremity orthopedic injuries that interfere with participation
Neurology, Sports Medicine, Muscle & Bone
I'm interested
Share via email
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,
State College, PA ,

PSCI 23-144 NRG-LU008: PHASE III PROSPECTIVE RANDOMIZED TRIAL OF PRIMARY LUNG TUMOR STEREOTACTIC BODY RADIATION THERAPYFOLLOWED BY CONCURRENT MEDIASTINAL CHEMORADIATION FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER

Patients diagnosed withy inoperable node positive non small cell lung cancer will be randomized to with radiation therapy to all know sites of disease in the lung, followed by immunotherapy or radiation to the primary lung tumor, followed by radiation to the lymph nodes followed by immunotherapy

Participants will be required to come to all study visits, report to the study doctor any new medications, prescription or over the counter that they may be taking,

Yes
 

Joseph Miccio
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Radiation Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05624996
STUDY00024448
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of Stage II or III (AJCC Eighth Edition) non-small cell lung cancer (NSCLC) with known PD-L1 status prior to registration.
The patient must be deemed clinically appropriate for curative intent definitive combined modality therapy, based on the following staging assessments:
No evidence of distant metastases based on FDG PET/CT scan obtainedwithin 60 days of registration.
Primary tumor ≤ 7 cm;
Age ≥ 18;

Exclusion Criteria:
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields that is determined by the treating physician to impede the treatment of the study malignancy.
Patients without identifiable primary tumor
Centrally located primary tumor < 2 cm from involved nodal disease which would result in significant overlap of the primary SBRT and nodal radiation fields
Participants who are pregnant or unwilling to discontinue nursing.
Participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) unwilling to use highly effective contraceptives during therapy
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Human Interaction with Information and Communication Technology

This study investigates users’ experience with Information and Communication Technology (ICTs). This study makes further implications for designing more user-friendly ICT for a better user experience. We aim to make such contributions by answering these questions:1.How do users interact with ICTs?2.What challenges do users face when using ICTs?3.What strategies do users apply to adapt themselves to ICTs?4.What service do ICT producers provide for users to get better user experience?5.When does user experience break down when interacting with ICTs?

No
 

Yao Lyu
Yao Lyu - at yml5549@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00016978
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or elder
all genders included
have prior experience with ICT
speak Madarin or English

Exclusion Criteria:
younger than 18 years old
vulnerable populations like cognitive impaired adults, prisoners.
no prior experience with ICT
speak neither Madarin nor English
I'm interested
Share via email

Normalizing preteen HPV vaccination with practice-based communication strategies (Protect Them)

This study seeks to adapt and test a culturally-relevant, web-based game intervention to motivate Spanish-speaking preteens to initiate and complete human papillomavirus (HPV) vaccination. The present study will adapt an existing web-based game developed as an educational tool on HPV vaccination for English-speaking preteens in North Carolina. The study includes the recruitment of paired dyads (Spanish-speaking preteens and parents) to focus groups to evaluate the acceptability of cultural adaptations to the existing web-based game intervention. We will recruit up to 25 parents and preteens ages 11-12 who will receive a link to the Spanish game to play for 7-10 days in advance of the focus group discussions. The focus groups will ask participants about cultural and language adaptations to the existing game and how they react to a game that will serve as an interactive, educational tool on HPV vaccination. The focus groups will take place in Harrisburg, PA between January and March of 2018. No health information will be collected as part of this study.

Yes
 

William Calo
William Calo - at wcalo@phs.psu.edu or 717-531-3535
Public Health Sciences (HERSHEY)
 

All
All
This study is also accepting healthy volunteers
SITE00000339
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pretens 11 or 12 years old
Not vaccinated with the HPV vaccine
Have computer, tablet, or smartphone

Exclusion Criteria:
Having received the HPV vaccine
Children's Health, Prevention
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,

How Immigration Looks to America: Perspectives of the Photographic Portrayals of Immigrants in News Photographs

This study will involve surveying college students regarding their perceptions about how immigrants are portrayed in news media.

No
 

Hans Schmidt
Hans Schmidt - at hcs10@psu.edu or 610-892-1251, ext=6108921251
Academic Affairs (BRANDYWINE)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014540
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Student at Penn State

Exclusion Criteria:
Below age 18
Education
I'm interested
Share via email

Dynamic Assessment of Vocabulary Learning Strategies

To provide better understanding of Chinese students' vocabulary learning Strategies and help develop better learning strategies

Complete seven sessions, which may take approximately 20-30 minutes of your time per session.Read several English short texts and identify meanings of target words.Possibly participate in a virtual interview that will be scheduled at your convenience.

No
 

Yuwei Xia
Yuwei Xia - at yxx5304@psu.edu or 626-999-1712
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021134
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Of Chinese origin or descent
Adult English learners
Currently enrolled in a college or university

Exclusion Criteria:
English as Native Language
Not Chinese
Education
Not applicable
I'm interested
Share via email

Watch Over: Using Apple Watches to Assess and Predict Substance Co-use in Young Adults

This study seeks to understand substance use and other health behaviors in young adults' daily lives. Interested participants can email the study team to complete a brief screener to see determine their eligibility. If eligible, participants will be asked to complete a short online survey and follow-up surveys for up to four weeks via a mobile device. Financial compensation will be provided.

This study involves three parts. First, potential participants will complete an online screener survey. If they are eligible, they will be immediately enrolled in the study and will proceed to the baseline survey. Second, participants who have completed the baseline portion of the study will schedule an in-person visit with the research team for the next portion of the study. At the start of the in-person visit, participants will be oriented about the study design which involves completing daily surveys about various health behaviors. Third, participants will come back in-person for a brief final visit and receive payment.

76

Yes
 

Saeed Abdullah
Sahiti Kunchay - at sahiti@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013672
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between 18-25 years of age
Current Penn State student
Currently owns and uses an iPhone with iOS version 15 or newer
Determined eligible through screener

Exclusion Criteria:
Eligibility determined using a screening survey
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

CCTG MA.39- A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Purpose of this study is to compare any good and bad effects of not using regional radiotherapy to using radiotherapy. The study will help researcher learn if not giving regional radiotherapy is just as good as using regional therapy to treat node positive breast cancer in women.

Blood will be drawn at two time points and number of visits will be determined by the individual radiation treatment plan.

Yes
 

Marc Rovito
Michelle Eschbach - at meschbach@pennstatehealth.psu.edu or 610-378-2336
Cancer Institute (ST. JOSEPH)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03488693
AFFILCCTGMA39
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Estrogen Receptor Positive / Her2 Negative Breast Cancer
No evidence of metastasis
1 - 3 positive lymph nodes
May have had breast conserving surgery or mastectomy
35 years of age or older

Exclusion Criteria:
Nodal disease limited to micromets or isolated cells
History of ipsilateral breast cancer or DCIS
Synchronous or contralateral breast cancer
pT4 disease
Neoadjuvant Chemotherapy for breast cancer
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Reading, PA ,

A Phase 3, single-arm, open-label, multicenter study of thesafety and efficacy of dirloctocogene samoparvovec(SPK-8011, adeno-associated viral vector with B-domaindeleted human factor VIII gene) in adults with severe ormoderately severe hemophilia A (KEYSTONESM 1)

This is a Phase 3 study of single-dose SPK-8011 AAV gene therapy in combination with immunomodulation. Patients will receive a one-time dose of SPK 8011, three weeks of methylprednisolone &amp; then will be followed for safety &amp; efficacy per study schedule.

1) Screening period of &lt; 8wks.-1 visit2) Lead-in for &gt;24 wks.-1 visit3) Pre-dose day -24-1 visit4) Dosing-Day 1 &amp; Day 2-2 visits5) Primary study (15 mos.)-37 visits6) Long term follow-up approx. 9 yrs.-20 visitsSome visits may be done via home health when a physical isn't required.

$75.00 travel reimbursement per visit

Yes
 

M. Elaine Eyster
Cynthia Campbell-Baird - at cbaird@psu.edu or 717-531-5777
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03003533
STUDY00022779
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult males (>18yrs.) with severe or moderately severe hemophilia A
>150 documented exposure days to a FVIII protein product
No evidence of cirrhosis or advanced liver disease
Negative test for inhibitor against FVIII during screening
No documented FVIII inhibitor in 5 yrs. prior to screening

Exclusion Criteria:
Positive anti-AAV Spark200NAb result
Currently undergoing antiviral therapy
Have an inherited bleeding or acquired disorder other than hemophilia A
Prior treatment with a vector or gene transfer agent
Major surgical procedure planned in a 15 month period following SPK 8011 infusion
Blood Disorders
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,